Diagnostic value of cancer-testis antigen mRNA in peripheral blood from hepatocellular carcinoma patients

Zhao, Li; Mou, Dong-Cheng; Peng, Jie; Huang, Lei; Wu, Zeng-An; Leng, Xi-sheng

doi:10.3748/wjg.v16.i32.4072

Cited by 13 publications

(7 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTp11 mRNA was expressed in 25-30% of the melanoma and bladder carcinoma cell lines tested, while only 2 of the 29 other tumor cell lines were positive. Recent studies reported a high frequency of CTp11 expression in 56.2% of HCC tissues and 31.1% of PBMC from HCC patients (31). In our study, CTp11 was expressed in 62% of HCC cell lines and 11% of HCC tissues.…”

Section: Discussionsupporting

confidence: 65%

Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma

et al. 2012

View full text Add to dashboard Cite

Cancer/testis (CT) antigens are considered promising target molecules for immunotherapy. To efficiently identify potential CT antigens, a testis cDNA library was immunoscreened with sera from hepatocellular carcinoma (HCC) patients. We isolated 3 different antigens, AKAP3, CTp11, and UBQLN3. Although AKAP3 and CTp11 have been previously reported as CT antigens, this is the first time that these 2 antigens have been isolated from HCC patients by SEREX. Conventional RT-PCR analysis showed that AKAP3 was frequently present in HCC cell lines (5/7) and HCC tissues (5/10), and the gene was broadly expressed in several cancer types, including breast cancer cell lines (3/6), breast cancer tissues (6/9), colon cancer cell lines (3/10), colon cancer tissues (5/6), ovary cancer cell lines (6/8), ovary cancer tissues (11/16), lung cancer cell lines (4/7) and lung cancer tissues (6/13). By phage plaque analysis, anti-AKAP3 antibody was detected in sera from 15 of 27 HCC patients and 8 of 27 healthy donors. These data suggest that AKAP3 may be useful for diagnosis and immunotherapy in HCC patients.

show abstract

Section: Discussionsupporting

confidence: 65%

Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Although 30%-40% of primary liver cancer is negative for AFP (29), it is still a sensitive tumor marker for the detection of HCC and a useful predictive factor due to its specificity for patient survival after locoregional or systemic treatment in HCC (30,31). A South Korean study reported that AFP normalization within 3 months after SBRT was a prognostic surrogate for OS and PFS in patients with small HCC (32).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Prognostic Factors of Trans-Arterial Chemoembolization Combined With Stereotactic Body Radiation Therapy for BCLC Stage B Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

PurposeThis study aimed to evaluate the efficacy and safety of trans-arterial chemoembolization (TACE) followed by stereotactic body radiation therapy (SBRT) in treating Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) not amenable to resection and radiofrequency ablation (RFA).MethodsFrom February 2012 to January 2017, a total of 57 BCLC stage B HCC patients who were unsuitable candidates for resection and RFA treated with TACE combined with CyberKnife SBRT were included in this retrospective study. Patients underwent TACE for a median of two times (1–5 times) before SBRT. SBRT prescription doses ranged from 30 Gy to 50 Gy in 3–5 fractions.ResultsThe median follow-up time was 42 months. The objective response rate (CR + PR) was 85.9%, and the disease control rate (CR + PR + SD) was 96.5%. The local control (LC) rates were 91.1% and 84.3% at 1 and 2 years, respectively. The 1-, 2-, 3-year overall survival (OS) and the median survival time were 73.2%, 51.4%, 32.4% and 26.6 months, respectively. The 1-, 2-, and 3-year progression-free survival (PFS) were 34.2%, 21.6%, and 9%, respectively, with a median PFS time of 9.7 months. A subgroup analysis was conducted in 32 patients with AFP ≥ 200 ng/ml before TACE. OS was significantly prolonged in those with AFP that decreased by more than 75% than those with AFP that decreased by less than 75% (P = 0.018) after SBRT. The treatment was well tolerated with only one patient (1.8%) developed grade 3 gastrointestinal toxicity, and another patient developed non-classical RILD. In multivariate analysis, tumor length ≥ 10 cm and AFP ≥ 200 ng/ml were independent poor prognostic factors for OS.ConclusionThe combination of TACE and Cyberknife SBRT showed optimal efficacy with acceptable toxicity for BCLC stage B HCC.

show abstract

“…Detection of serum alpha-fetoprotein (AFP) is used in clinical follow-up for high-risk population screening and cancer patients. Although 30% ~ 40% of patients have negative AFP detection in HCC of China [ 14 ], due to its characteristics of high specificity, it is still of significant value in clinical examination. In this study, the selected patients had AFP levels greater than 400 ng/mL before the first TACE treatment.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Stereotactic Body Radiotherapy for Recurrent or Residual Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization

Yao

Chen

Zhao

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Aim To evaluate the efficacy and toxicity of hypofractionated stereotactic body radiotherapy (SBRT) for patients with recurrent or residual hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). Methods Between June 2008 and July 2015, thirty-three patients with HCC were treated by SBRT. There were 63 lesions in 33 patients. A total dose of 39–45 Gy/3–5 fractions was delivered to the 70–80% isodose line. Results Objective response rate (CR + PR) was 84.8% at 6 months. The overall survival rate was 87.9%, 75.8%, 57.6%, and 45.5% at 6, 12, 18, and 24 months, respectively. Median overall survival was 19 months. At 3 months, AFP decreased by more than 75% in 51.5% of patients (17/33). Overall survival was significantly different (P < 0.001) between the group of patients for whom AFP decreased more than 75% and the group for whom AFP decreased by less than 75%. The AFP-negative rate was 48.5% (16/33) after 6 months. Eight patients (24.2%) had grade 1-2 transient fatigue, and 11 patients (33.3%) had grade 1-2 gastrointestinal reactions within 1 month. Conclusion SBRT is a promising noninvasive and palliative treatment with acceptable toxicity for recurrent or residual HCC after TACE.

show abstract

Diagnostic value of cancer-testis antigen mRNA in peripheral blood from hepatocellular carcinoma patients

Abstract: Detecting MAGE-1, SSX-1 and CTp11 mRNA in PBMC improves the total diagnostic rate of HCC.

Cited by 13 publications

References 41 publications

Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma

Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma

Efficacy and Prognostic Factors of Trans-Arterial Chemoembolization Combined With Stereotactic Body Radiation Therapy for BCLC Stage B Hepatocellular Carcinoma

Efficacy of Stereotactic Body Radiotherapy for Recurrent or Residual Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization

Contact Info

Product

Resources

About